2-异氰酸对苯二甲酸二甲酯 | 179114-94-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-异氰酸对苯二甲酸二甲酯
• 英文名称: dimethyl 2-isocyanatoterephthalate
• 英文别名: dimethyl 2-isocyanatobenzene-1,4-dioate；dimethyl 2-isocyanatobenzene-1,4-dicarboxylate
• CAS: 179114-94-4
• 化学式: C₁₁H₉NO₅
• mdl: MFCD10699354
• 分子量: 235.196
• InChiKey: VLBOVVSWDHUHJK-UHFFFAOYSA-N

物化性质

• 熔点：
  115-117 °C
• 沸点：
  350.3±32.0 °C(Predicted)
• 密度：
  1.24±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  82
• 氢给体数：
  0
• 氢受体数：
  6

安全信息

• 危险等级：
  IRRITANT

反应信息

• 作为反应物：
  描述：

  2-异氰酸对苯二甲酸二甲酯 在 sodium hydroxide 、 三乙胺 作用下， 以 1,4-二氧六环 、 甲醇 、 水 为溶剂， 生成 3-methyl-2,4-dioxo-1,2,3,4-tetrahydro-quinazoline-7-carboxylic acid
  参考文献：
  名称：

  Novel T-type calcium channel blockers: Dioxoquinazoline carboxamide derivatives

  摘要：

  T-type calcium channel is one of therapeutic targets for the treatment of cardiovascular diseases and neuropathic pains. Since the withdrawal of mibefradil, a T-type calcium channel blocker, there have been a lot of efforts to develop T-type calcium channel blockers. A small molecule library of dioxoquinazoline carboxamide derivatives containing 155 compounds was designed, synthesized, and biologically evaluated for T-type calcium channel blocking activity. Among those compounds synthesized, the compound In shows the most potent T-type calcium current blocking activity with an IC50 value of 1.52 mu M, which is comparable to that of mibefradil. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2006.09.051
• 作为产物：
  描述：

  2-氨基对苯二甲酸二甲酯 在 硫酸 作用下， 以 甲苯 为溶剂， 反应 0.5h， 生成 2-异氰酸对苯二甲酸二甲酯
  参考文献：
  名称：

  Organosilicon synthesis of isocyanates: III. Synthesis of aliphatic, carbocyclic, aromatic, and alkylaromatic isocyanatocatboxylic acid esters

  摘要：

  A series of aminoacid esters was prepared by treating the aminoacid suspensions in ethanol with thionyl chloride. Best conversion of aminoacid esters to corresponding isocyanates was achieved in the case of aromatic and carbocyclic aminoesters by phosgeneation of their N-silyl derivatives, and in the case of aliphatic and alkylaromatic aminoesters by phosgeneation of O-silyl or N,O-bissilylurethanes on their basis. In the last case additional step of esterification of the by-products isocyanatoalkylcarboxylic acid chlorides is reqired after phosgeneation. Unusual generation of cynnamates and intramolecular N -> O-migration of trimethylsilyl group in the solutions of silylated alkylaromatic beta-aminoacid esters were found.

  DOI：

  10.1134/s1070363206070115

文献信息

• One-Pot Synthesis of 1-Hydroxyacridones from <i>para</i>-Quinols and <i>ortho</i>-Methoxycarbonylaryl Isocyanates
  作者：Jing Wu、Jinzhu Zhang、Ruben Soto-Acosta、Lili Mao、Jiahui Lian、Kenny Chen、Guy Pillon、Guoqi Zhang、Robert J. Geraghty、Shengping Zheng

  DOI：10.1021/acs.joc.9b03307

  日期：2020.3.20

  A variety of substituted acridones were synthesized via a one-pot, metal-free cascade reaction. In this event, the DBU-mediated addition between quinols and ortho-methoxycarbonylaryl isocyanates formed a bicyclic oxazolidinone, followed by a sequence of intramolecular condensation, tautomerization, and decarboxylation, which led to the formation of acridones. The acridones showed mild activity against

  通过一锅、无金属级联反应合成了多种取代的吖啶酮。在这种情况下，DBU 介导的醌醇和邻甲氧基羰基芳基异氰酸酯之间的加成形成了双环恶唑烷酮，然后进行了一系列分子内缩合、互变异构和脱羧，从而形成了吖啶酮。吖啶酮对人巨细胞病毒表现出温和的活性。
• PHARMACEUTICAL COMPOSITIONS CONTAINING QUINAZOLINE DERIVATIVES FOR TREATING AS SEROTONIN RECEPTOR ANTAGONIST
  申请人：NAM Ghil Soo

  公开号：US20090054433A1

  公开（公告）日：2009-02-26

  The present invention relates to a pharmaceutical composition containing one or more quinazoline compounds as an active ingredient, which has antagonistic activity against serotonin 5-HT 3 A and is effective for the prevention and treatment of central nervous system (CNS) diseases, including emesis, nausea, alcoholism, drug abuse, depression, compulsive neurosis, anxiety, seizure, Alzheimer's disease, Parkinson's disease, Huntington's chorea, psychosis, schizophrenia, suicidal tendency, sleep disorder, appetite disorder and migraine.

  本发明涉及一种药物组合物，其包含一种或多种喹唑啉化合物作为活性成分，具有对5-HT3A血清素拮抗活性，并且对预防和治疗中枢神经系统（CNS）疾病有效，包括呕吐、恶心、酗酒、药物滥用、抑郁症、强迫神经症、焦虑、癫痫、阿尔茨海默病、帕金森病、亨廷顿舞蹈症、精神病、精神分裂症、自杀倾向、睡眠障碍、食欲障碍和偏头痛。
• Pharmaceutical compositions containing quinazoline derivatives for treating as serotonin receptor antagonist
  申请人：Nam Ghil Soo

  公开号：US08748422B2

  公开（公告）日：2014-06-10

  The present invention relates to a pharmaceutical composition containing one or more quinazoline compounds as an active ingredient, which has antagonistic activity against serotonin 5-HT3A and is effective for the prevention and treatment of central nervous system (CNS) diseases, including emesis, nausea, alcoholism, drug abuse, depression, compulsive neurosis, anxiety, seizure, Alzheimer's disease, Parkinson's disease, Huntington's chorea, psychosis, schizophrenia, suicidal tendency, sleep disorder, appetite disorder and migraine.

  本发明涉及一种药物组合物，包含一种或多种喹唑啉类化合物作为活性成分，具有对5-HT3A血清素的拮抗活性，并对中枢神经系统（CNS）疾病的预防和治疗有效，包括呕吐、恶心、酗酒、药物滥用、抑郁症、强迫神经症、焦虑症、癫痫、阿尔茨海默病、帕金森病、亨廷顿舞蹈症、精神病、精神分裂症、自杀倾向、睡眠障碍、食欲障碍和偏头痛。
• WO2008/7835
  申请人：——

  公开号：——

  公开（公告）日：——
• Structure−Activity Studies for a Novel Series of Bicyclic Substituted Hexahydrobenz[<i>e</i>]isoindole α_1A Adrenoceptor Antagonists as Potential Agents for the Symptomatic Treatment of Benign Prostatic Hyperplasia
  作者：Michael D. Meyer、Robert J. Altenbach、Hao Bai、Fatima Z. Basha、William A. Carroll、James F. Kerwin、Suzanne A. Lebold、Edmund Lee、John K. Pratt、Kevin B. Sippy、Karin Tietje、Michael D. Wendt、Michael E. Brune、Steven A. Buckner、Arthur A. Hancock、Irene Drizin

  DOI：10.1021/jm000541z

  日期：2001.6.1

  In search of a uroselective alpha (1A) subtype selective antagonist, a novel series of 6-OMe hexahydrobenz [e]isoindoles attached to a bicyclic heterocyclic moiety via a two-carbon linker was synthesized. It was found that in contrast to the previously described series of tricyclic heterocycles,l this bicyclic series has very specific requirements for the heterocyclic attachments. The most important structural features contributing to the alpha (1A)/alpha (1B) selectivity of these compounds were identified. In vitro functional assays for the al adrenoceptor subtypes were used to further characterize the most selective compounds, and in vivo models of vascular vs prostatic tone were used to assess uroselectivity. Compound 48 showed the highest degree of selectivity in the radioligand binding assays (56-fold), in the in vitro functional tests (80-fold), and for in vivo prostate selectivity (960-fold).